Stevens Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
JFG
Stevens Capital Management's XBI Position: Q2 2026 in Review
Stevens Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 18% in Q2 2026, selling an estimated $183K and leaving 6,162 shares worth $975K. The position accounts for 0.23% of the portfolio, ranked #90.
Stevens Capital Management first reported a position in XBI in Q3 2020 and has held it in 16 quarters since. The position peaked at $14M in Q4 2020. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Stevens Capital Management held 6,162 shares of State Street SPDR S&P Biotech ETF worth $975K as of Q2 2026.
- Stevens Capital Management sold 1,351 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $183K.
- State Street SPDR S&P Biotech ETF made up 0.23% of Stevens Capital Management's portfolio in Q2 2026, its #90 holding.
- Stevens Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and has held it in 16 quarters since.
- Stevens Capital Management's State Street SPDR S&P Biotech ETF position peaked at $14M in Q4 2020.
- 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Stevens Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.